Related Experiment Videos
T-cell antigen receptor transmembrane peptides modulate T-cell function and T cell-mediated disease
N Manolios1, S Collier, J Taylor
1Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Sydney, NSW, Australia.
Nature Medicine
|January 1, 1997
Summary
A novel peptide inhibits T-cell function by targeting T-cell receptor assembly. This core peptide (CP) shows potential for treating inflammatory and autoimmune disorders.
Area of Science:
- Immunology
- Molecular Biology
- Drug Discovery
Background:
- T-cell dysfunction underlies many inflammatory and autoimmune diseases.
- Targeting T-cell receptor (TCR) assembly offers a novel therapeutic strategy.
- Understanding TCR alpha-chain interactions is crucial for modulating T-cell responses.
Purpose of the Study:
- To develop and characterize a novel peptide inhibitor of T-cell function.
- To investigate the therapeutic potential of this peptide in T-cell-mediated inflammatory diseases.
Main Methods:
- Rational design of peptides based on the TCR alpha-chain transmembrane sequence.
- In vitro assessment of T-cell function modulation (e.g., IL-2 production).
- In vivo efficacy testing in three distinct T-cell-mediated disease models.
Main Results:
- A nine-amino acid core peptide (CP) effectively modulated T-cell function in vitro and in vivo.
- CP demonstrated cell permeability without chemical modification.
- Palmitic acid conjugation enhanced IL-2 inhibition.
- CP reduced inflammation in adjuvant-induced arthritis, experimental allergic neuritis, and autoimmune diabetes models.
Conclusions:
- The rationally designed core peptide (CP) is a potent inhibitor of T-cell function.
- CP exhibits therapeutic potential for human inflammatory and autoimmune disorders.
- Further development of CP or its analogues could lead to new treatments.